Clinical trials remain the most expensive, slowest, and highest-risk phase of therapeutic development. The average Phase III costs $100-300M, takes 3-5 years, and has a failure rate that hasn't meaningfully improved in decades. The root cause is not a lack of good science — it is a lack of decision intelligence at the design stage, where trial architecture decisions lock in costs, timelines, and risk profiles that compound through execution.
Behavior Labs delivers decision intelligence for clinical trial design and optimization — connecting synthetic phenotyping, adaptive design modeling, endpoint precedent analysis, enrollment simulation, and regulatory pathway intelligence into a platform that de-risks trial architecture before a single patient is enrolled.
The Phase II to Phase III transition is the most expensive decision point in pharmaceutical development. The trial design decisions made here — endpoints, comparator arms, enrichment strategy, adaptive triggers, enrollment geography — lock in hundreds of millions in cost and years of timeline. Better intelligence at this moment changes everything downstream.
Generate synthetic patient populations to identify responder subgroups before enrollment begins. Phenotype stratification has shown potential to reduce required sample sizes by 30-40% — saving tens of millions in trial execution costs and compressing timelines by a year or more.
Simulate adaptive trial architectures — interim analysis triggers, sample size re-estimation, dose selection, population enrichment — before committing to a design. Model the decision rules that balance statistical rigor with operational efficiency.
Generate external control arms from synthetic data and real-world evidence to reduce placebo burden, accelerate enrollment, and support regulatory submissions. Particularly valuable for rare diseases, pediatric populations, and indications where placebo arms face ethical constraints.
Analyze endpoint acceptance patterns across FDA and EMA for your mechanism class. Benchmark your endpoint selection against competitor programs and regulatory precedent to avoid the submission surprises that derail timelines — like an FDA feedback letter questioning your primary endpoint choice.
Trial design decisions made before enrollment account for the largest share of program cost, timeline, and risk. Better design intelligence compounds through execution.
See how decision intelligence at the design stage de-risks the most expensive decision in pharmaceutical development.
